Search
amivantamab (Rybrevant)
Indications:
- non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation(s)
Dosage:
- 1050 mg if < 80 kg
- 1400 mg if > 80 kg
Adverse effects:
- rash (86%)
- acneiform eruption [3]
- suppurative folliculitis with psoriasiform epidermal hyperplasia [3]
- infusion-related reactions (66%)
- paronychia (45%), nail dystrophy, onycholysis [3]
- stomatitis (21%)
- pruritus (17%)
- diarrhea (12%)
* No treatment-related deaths
* adverse events leading to dose reductions (13%) & discontinuation (4%)
* discontinue if symptoms of interstitial lung disease
* limit sun exposure during treatment & for 2 months after treatment
* amivantamab may cause problems with vision.
Laboratory:
- Guardant360 CDx FDA approved as a companion diagnostic test
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
antineoplastic monoclonal antibody
References
- Mulcahy N
FDA OKs First Targeted Therapy for Subset of Patients With NSCLC
Medscape - May 21, 2021.
https://www.medscape.com/viewarticle/951644
- Kuehn BM
New Targeted Non-Small Cell Lung Cancer Therapy Approved.
JAMA. 2021;326(1):20. July 6.
PMID: 34228082
https://jamanetwork.com/journals/jama/fullarticle/2781663
- Belzer A, Nguyen MO, Talsania A et al.
Spectrum of Dermatologic Adverse Events Associated With Amivantamab Use.
JAMA Dermatol. Published online November 23, 2022
PMID: 36416832
https://jamanetwork.com/journals/jamadermatology/fullarticle/2798498